Lipinski for mAbs

As therapeutic antibodies mature as a modality, Adimab LLC is aiming to streamline discovery by developing a set of standards -- analogous to the "Lipinski rule of five" for small molecules -- that can identify mAbs with drug-like properties, and has published a study analyzing the biophysical characteristics of 137 compounds.

Yingda Xu, Adimab director of protein analytics, told BioCentury the company took on the challenge in response to high rates of clinical failures within the modality. “We noticed a lot of therapeutic antibody discovery programs failed, not because they didn’t have the right biology, but they had development issues from purification all the way to immunogenicity.” ...